Baiyin

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Researchers are evaluating HS-20093, a fully humanized antibody-drug conjugate targeting B7-H3, which is commonly found on solid tumor cells. This phase 2, open-label, multi-center study aims to investigate the anti-tumor activity, safety, and pharmacokinetics of HS-20093 in Chinese patients with metastatic castration resistant prostate cancer (mCRPC) and other advanced solid tumors who have progressed on or are intolerant to standard therapies. The study includes two parts: Phase 2a and Phase 2b. In Phase 2a, patients with mCRPC and other advanced solid tumors will receive HS-20093 at a dose of 8 mg/kg. Phase 2b focuses on patients with mCRPC receiving the same dosage. HS-20093 is given intravenously every three weeks, and participants continue treatment until disease progression, unacceptable toxicity, or study end. Patients may continue therapy if the treatment is well tolerated and shows ongoing clinical benefit. Participants will be closely monitored for adverse effects during treatment and for 90 days after the last dose. Researchers will assess tumor response up to 24 months from the first dose or until disease progression or withdrawal. Evaluations include safety, tolerability, pharmacokinetics, and objective response rate. The study requires patients to have measurable lesions and agree to provide tumor tissue for analysis, with follow-up for treatment effects and safety throughout the study period.

Researchers are evaluating the effectiveness and safety of a chemotherapy drug called JSKN003 compared to other chemotherapy treatments chosen by doctors for adults with HER2-low, unresectable, or metastatic breast cancer. This study focuses on patients whose cancer has returned or spread and who have already tried one or two previous chemotherapy treatments without success. It is a phase III, open-label, randomized study conducted at multiple centers. Participants will be randomly assigned to one of two groups: one group will receive JSKN003 given through an intravenous infusion according to the study plan, while the other group will receive one of several chemotherapy drugs selected by their doctor before joining the study. These options include capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. Treatment is given as a single drug in both groups. During the study, participants will be monitored for up to about three years to see how long they live without their cancer worsening. Researchers will conduct imaging scans, lab tests, and other evaluations to track disease progression and overall health. Safety and side effects will be carefully observed, and participants' tumor samples will be analyzed to confirm HER2 status. The study aims to enroll 408 subjects and includes follow-up assessments to ensure continued monitoring of treatment outcomes.

Researchers are investigating the effects of quizartinib compared to a placebo, both combined with chemotherapy, in adults newly diagnosed with FLT3-internal tandem duplication (ITD) negative acute myeloid leukemia (AML). This phase 3 clinical trial focuses on overall survival as the primary outcome and involves testing participants for FLT3-ITD mutation status at a central laboratory using a validated assay. Participants will receive either quizartinib or placebo at a dose of 60 mg taken orally once daily. Both groups will also receive standard induction and consolidation chemotherapy using cytarabine and an anthracycline (daunorubicin or idarubicin). After chemotherapy, quizartinib or placebo will be administered as maintenance therapy for up to 36 cycles. During the study, participants will be monitored for overall survival up to approximately 42 months from when the first patient is randomized to reach the target number of deaths. The study involves regular assessments including treatment monitoring and safety evaluations throughout the induction, consolidation, and maintenance phases to evaluate the effect of quizartinib in this patient population.

Researchers are studying adult patients in China with resected stage II to IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). The study aims to evaluate the clinical outcomes and characteristics of these patients when treated with Alectinib as adjuvant therapy after surgery. This is a multicenter, prospective, observational cohort study focusing on this specific lung cancer subgroup. Participants in this study have already received Alectinib monotherapy as adjuvant treatment following complete surgical removal of their cancer. There is no additional intervention provided by the study as it is observational. The study includes patients who started Alectinib within 28 days before enrollment and have not received prior systemic therapies such as other ALK inhibitors or chemotherapy. Throughout the study, researchers will collect data on real-world disease-free survival, tracking the time from baseline until either cancer recurrence or death from any cause for up to approximately 2.5 years. The study observes patients under routine clinical care to understand the effectiveness and safety of Alectinib in this setting, with no extra treatments or procedures mandated by the study protocol.

Researchers are evaluating the safety, tolerability, and characteristics of a drug called Rina-S in people with various advanced solid tumors that have spread or cannot be removed by surgery. This includes cancers such as ovarian, endometrial, breast, non-small cell lung cancer, and mesothelioma. The study is a Phase 1/2 trial designed to assess how the drug works and its effects on these cancers. Participants will receive intravenous infusions of Rina-S alone or in combination with other drugs like Carboplatin, Bevacizumab, or Pembrolizumab. The study is divided into multiple parts focusing on different tumor types and treatment combinations, including monotherapy and combination therapy cohorts. Treatments continue until disease progression, unacceptable side effects, or other reasons for stopping treatment. During the study, participants will undergo various assessments including safety monitoring for side effects and dose-limiting toxicities, tumor response evaluations using imaging criteria, and heart monitoring with electrocardiograms for some participants. Researchers will track treatment-emergent adverse events for up to about one year. Participants remain involved through treatment cycles and follow-up evaluations to understand the drug's effects and safety profile.